A Virginia Tech study could strike a new chord in the world of treatment for attention deficit hyperactivity disorder or ADHD ...
MedPage Today on MSN
Next DSM insights; FDA reviewing non-stimulant ADHD drug; 10M people microdosing
News and commentary from the psychiatry world ...
The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...
Otsuka Pharmaceutical Co. Ltd. filed an NDA with the U.S. FDA for centanafadine (formerly EB-1020), a new nonstimulant therapy for treating attention-deficit hyperactivity disorder (ADHD) in children, ...
From 2022 to 2024, stimulant prescriptions issued in Connecticut increased by 13.2 percent, according to data from the state.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results